Friday, July 10, 2026

Drug profile · INN

tinzaparin sodium

tinzaparin sodium (INNOHEP) is a antithrombin-iii activator. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — tinzaparin sodium
US status
approved
Class
Route
INJECTION
Patents
0
Programs
1
Data quality
0.84

Quick answer

tinzaparin sodium (INNOHEP) is a antithrombin-iii activator. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN tinzaparin sodium
Brand INNOHEP
Mechanism Antithrombin-III activator
Target Antithrombin-III
Route INJECTION
Formulation INJECTABLE

Mechanism of action

Antithrombin-III activator

Primary target: Antithrombin-III

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. imPaCT-PRO-01 Phase 3 · George Institute for · Thromboprophylaxis in patients with advanced pancreatic canc

Related & competitor drugs

  1. enoxaparin sodium Blood and blood forming organs (B01)
  2. fondaparinux sodium Blood and blood forming organs (B01)
  3. heparin sodium Antithrombin-III activator
  4. ardeparin sodium Antithrombin-III activator
  5. dalteparin sodium Antithrombin-III activator
  6. danaparoid sodium Antithrombin-III activator

Frequently asked questions

What is tinzaparin sodium?

tinzaparin sodium (INNOHEP) is a antithrombin-iii activator. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for tinzaparin sodium?

INNOHEP is a marketed brand name for tinzaparin sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of tinzaparin sodium?

tinzaparin sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.